Information Provided By: 
Fly News Breaks for April 6, 2018
PTN
Apr 6, 2018 | 07:06 EDT
H.C. Wainwright analyst Joseph Pantginis started Palatin Technologies with a Buy rating and $5 price target. The analyst views the company's lead asset bremelanotide, which is in development for hypoactive sexual desire disorder in women, as "significantly derisked." He believes the drug's "checked boxes" and projected catalysts are not reflected in the current share price.
News For PTN From the Last 2 Days
There are no results for your query PTN
